TY - JOUR
T1 - Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors
AU - Mukherjee, Akash
AU - Milton, Denái R.
AU - Jabbour, Elias J.
AU - Gulbis, Alison M.
AU - Kadia, Tapan
AU - Jain, Nitin
AU - Ledesma, Celina
AU - Burger, Jan
AU - Ferrajoli, Alessandra
AU - Wierda, William
AU - Medeiros, L. Jeffrey
AU - Kantarjian, Hagop
AU - Champlin, Richard
AU - Khouri, Issa F.
N1 - Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - We aimed to study the risks of graft-versus-host disease (GVHD), non-relapse mortality (NRM) and survival outcomes of allogeneic stem cell transplantation (alloSCT) in patients with chronic lymphocytic leukemia (n = 17), Richter’s syndrome (n = 14), or lymphoma (n = 18) after small molecule inhibitors (SMIs). Patients had a median of 4 prior therapies, including ibrutinib (n = 46; 94%), venetoclax (n = 19; 39%), and idelalisib (n = 6; 12%). Twenty-one (43%) had >1 SMI. P53 mutation was detected in 58% of patients. The 3-year overall and progression-free survival rates were 68% and 59%, respectively. The rates of grade II–IV and III–IV acute GVHD were 33% and 7%. The 1-year rates of chronic GVHD, NRM and relapse were 19%, 10% and 21%, respectively. Results were comparable to a historical control of patients who received alloSCT without a prior exposure to SMI. We conclude that a prior use of SMI does not impair the outcomes after alloSCT.
AB - We aimed to study the risks of graft-versus-host disease (GVHD), non-relapse mortality (NRM) and survival outcomes of allogeneic stem cell transplantation (alloSCT) in patients with chronic lymphocytic leukemia (n = 17), Richter’s syndrome (n = 14), or lymphoma (n = 18) after small molecule inhibitors (SMIs). Patients had a median of 4 prior therapies, including ibrutinib (n = 46; 94%), venetoclax (n = 19; 39%), and idelalisib (n = 6; 12%). Twenty-one (43%) had >1 SMI. P53 mutation was detected in 58% of patients. The 3-year overall and progression-free survival rates were 68% and 59%, respectively. The rates of grade II–IV and III–IV acute GVHD were 33% and 7%. The 1-year rates of chronic GVHD, NRM and relapse were 19%, 10% and 21%, respectively. Results were comparable to a historical control of patients who received alloSCT without a prior exposure to SMI. We conclude that a prior use of SMI does not impair the outcomes after alloSCT.
KW - AllosSCT
KW - b-cell malignancies
KW - small molecule inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85125902165&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125902165&partnerID=8YFLogxK
U2 - 10.1080/10428194.2022.2043302
DO - 10.1080/10428194.2022.2043302
M3 - Article
C2 - 35225133
AN - SCOPUS:85125902165
SN - 1042-8194
VL - 63
SP - 885
EP - 893
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 4
ER -